Sodium Potassium Chloride Symporter Inhibitors
"Sodium Potassium Chloride Symporter Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA.
| Descriptor ID |
D049994
|
| MeSH Number(s) |
D27.505.519.562.906 D27.505.696.560.500.931
|
| Concept/Terms |
Sodium Potassium Chloride Symporter Inhibitors- Sodium Potassium Chloride Symporter Inhibitors
- Na-K-CL Symporter Inhibitors
- Inhibitors, Na-K-CL Symporter
- Na K CL Symporter Inhibitors
- Symporter Inhibitors, Na-K-CL
- Sodium Potassium Chloride Cotransporter Inhibitors
- Bumetanide Sensitive Na-K-Cl-Transporter Inhibitors
- Bumetanide Sensitive Na K Cl Transporter Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Sodium Potassium Chloride Symporter Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Sodium Potassium Chloride Symporter Inhibitors".
This graph shows the total number of publications written about "Sodium Potassium Chloride Symporter Inhibitors" by people in this website by year, and whether "Sodium Potassium Chloride Symporter Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 2 | 0 | 2 |
| 2017 | 3 | 3 | 6 |
| 2018 | 5 | 2 | 7 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sodium Potassium Chloride Symporter Inhibitors" by people in Profiles.
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.
-
Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study. J Infect. 2021 Jan; 82(1):e22-e24.
-
Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 09; 360(3):216-221.
-
Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. J Am Heart Assoc. 2019 07 16; 8(14):e012244.
-
Characteristics and treatment strategies for severe tricuspid regurgitation. Heart. 2019 08; 105(16):1244-1250.
-
EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging. 2019 04; 36(4):299-307.
-
Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019 05; 21(5):624-633.
-
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovasc Drugs Ther. 2019 02; 33(1):77-86.
-
Audits of clinical practice should be encouraged. Use of loop diuretics in patients without a diagnosis of heart failure should be discouraged. Eur J Prev Cardiol. 2019 02; 26(3):289-290.
-
Older drugs with infantile evidence: the illustrative example of loop diuretics. Eur Heart J Qual Care Clin Outcomes. 2018 07 01; 4(3):232-234.